Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Nitrendipine receptor Synaptic scaling up is induced within
2023-04-17

Synaptic scaling up is induced within primary visual Nitrendipine receptor (V1) by brief sensory deprivation (Desai et al., 2002; Lambo and Turrigiano, 2013). Several studies have examined the transcriptional changes within extracts of V1 following visual deprivation protocols (Lachance and Chaudhu
-
leukotriene receptor agonist In conclusion our study would
2023-04-17

In conclusion, our study would seem to indicate that a hydrophilic microenvironment, which is suitable to accommodate highly hydrophilic molecules with steric hindrance such as aldose hemiacetals, allows the enzyme modulation by one of its most important physiopathological substrates. It is difficul
-
AKT activity is also self limiting through its substrate GSK
2023-04-17

AKT activity is also self-limiting through its substrate GSK3β; the kinase activity of which is negatively regulated by AKT phosphorylation (Fig. 3; Li, Liu, & Gao, 2009). GSK3β activation results in phosphorylation and subsequent ubiquitin mediated degradation of PHLPP (Li et al., 2009). AKT activa
-
Interestingly hypoxia and an enhanced Warburg effect
2023-04-17

Interestingly, hypoxia and an enhanced Warburg effect ultimately lead to increased lactate production. The accumulation of lactate results in an acidic tumor microenvironment, which induces local inflammation. Lactate also promotes the polarization of macrophages that express immunosuppressive argin
-
The rank order of agonist potency in turkey cardiac chambers
2023-04-17

The rank order of agonist potency in turkey cardiac chambers demonstrated the predominant presence of the β-adrenergic receptor subtype, in line with the receptor classification by . However, a previous radioligand binding study in the left ventricles of 7-week old turkeys reported the existence of
-
br Experimental procedure br Introduction Migraine is a
2023-04-17

Experimental procedure Introduction Migraine is a debilitating neurovascular disorder characterized by recurring unilateral pulsating headaches of moderate to severe intensity, associated with nausea, photophobia and/or phonophobia, lasting from 4 to 72 h (Headache Classification Committee of
-
The potential use of derivatives belonging to this series as
2023-04-17

The potential use of derivatives belonging to this series as therapeutic agents mostly depends on their pharmacokinetics and pharmacodynamics. The pharmacokinetic phase includes absorption, distribution, metabolism and excretion (ADME) of the studied compounds. Therefore, preliminary data for theore
-
RG7112 sale br Methods and results ACE is a Canadian
2023-04-17

Methods and results ACE is a Canadian satellite mission [7] that measures atmospheric RG7112 sale spectra in the limb geometry using the Sun as a light source (solar occultation). The ACE orbit (74° inclination to the equator, 650 km altitude) concentrates measurements at high latitudes but also
-
br ARIs in the prevention of prostate cancer Prostate
2023-04-17

5ARIs in the prevention of prostate cancer Prostate cancer continues to be a leading cause of male deaths worldwide. In 2009, it was estimated there would be 192,280 new cases of prostate cancer with a predicted 27,360 deaths [25]. Because androgens, and specifically DHT, play a large role in bot
-
br Author contributions br Conflict of interest br Acknowled
2023-04-17

Author contributions Conflict of interest Acknowledgements This work was supported by the National Natural Science Foundation of China (81502276), Major Projects of Science and Technology of Health and Family Planning Commission of Hunan Province (A2017013), the Natural Science Foundation o
-
Using our infection assays we
2023-04-17

Using our infection assays, we also explored whether low-pH compartments were required for the entry of ZIKVs in mammalian cells. Lysosomotropic agents such as ammonium chloride, chloroquine and Bafilomycin A1, strongly inhibited the ability of ZIKVs to enter mammalian cells. Our results are in agre
-
l-name mg PD research involves the use of
2023-04-17

PD research involves the use of many animal models, which can be categorized into two main types: toxic models—among which the two most widely used are the classical 6-hydroxydopamine (6-OHDA) model in rats and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model in mice and monkeys—and gen
-
Additional support for a role of HMGN
2023-04-17

Additional support for a role of HMGN1 in enhancing DNA repair comes from studies of transcription-coupled repair (TCR) in human cells. Lesions in the template strand of DNA induced by UV light stall the movement of RNA polymerase II (RNAPII) and interrupt transcription. Removal of these transcripti
-
AZD6244 We report here the first study on
2023-04-17

We report here the first study on the inhibitory effects of the organic nitrates – on human erythrocyte GR. The previous reports by Becker et al., investigated other nitro derivatives (including arylizoalloxazines) by using Beutler’s method, monitoring GR inhibition. Data of show inhibition of hGR
-
The major phase trial NCT enrolled participants with mild to
2023-04-14

The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef
15740 records 336/1050 page Previous Next First page 上5页 336337338339340 下5页 Last page